 Neoplasm Metastasis
"Neoplasm Metastasis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Descriptor ID |
D009362
|
| MeSH Number(s) |
C04.697.650 C23.550.727.650
|
| Concept/Terms |
Neoplasm Metastasis- Neoplasm Metastasis
- Metastases, Neoplasm
- Neoplasm Metastases
- Metastasis
- Metastases
- Metastasis, Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Metastasis".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Metastasis".
This graph shows the total number of publications written about "Neoplasm Metastasis" by people in this website by year, and whether "Neoplasm Metastasis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 1996 | 1 | 4 | 5 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 4 | 4 | | 2000 | 0 | 4 | 4 | | 2001 | 1 | 2 | 3 | | 2002 | 1 | 5 | 6 | | 2003 | 3 | 7 | 10 | | 2004 | 1 | 9 | 10 | | 2005 | 1 | 10 | 11 | | 2006 | 0 | 6 | 6 | | 2007 | 1 | 7 | 8 | | 2008 | 1 | 5 | 6 | | 2009 | 3 | 16 | 19 | | 2010 | 4 | 14 | 18 | | 2011 | 1 | 14 | 15 | | 2012 | 2 | 14 | 16 | | 2013 | 2 | 22 | 24 | | 2014 | 1 | 24 | 25 | | 2015 | 4 | 21 | 25 | | 2016 | 3 | 37 | 40 | | 2017 | 2 | 33 | 35 | | 2018 | 0 | 27 | 27 | | 2019 | 2 | 18 | 20 | | 2020 | 3 | 17 | 20 | | 2021 | 0 | 9 | 9 | | 2022 | 3 | 1 | 4 | | 2023 | 1 | 0 | 1 | | 2024 | 0 | 13 | 13 | | 2025 | 0 | 5 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasm Metastasis" by people in Profiles.
-
Rosenbaum SR, Hughes CJ, Fields KM, Purdy SC, Gustafson AL, Wolin A, Hampton D, Shrivastava NM, Turner N, Danis E, Ebmeier C, Spoelstra N, Richer J, Jedlicka P, Costello JC, Zhao R, Ford HL. EYA3 regulation of NF-?B and CCL2 suppresses cytotoxic NK cells in the premetastatic niche to promote TNBC metastasis. Sci Adv. 2025 May 09; 11(19):eadt0504.
-
Edwards DN, Wang S, Kane K, Song W, Kim LC, Ngwa VM, Hwang Y, Ess K, Boothby MR, Chen J. Increased fatty acid delivery by tumor endothelium promotes metastatic outgrowth. JCI Insight. 2025 May 08; 10(9).
-
Flynn A, Pattison AD, Balachander S, Boehm E, Bowen B, Dwight T, Rossello FJ, Hofmann O, Martelotto L, Zethoven M, Kirschner LS, Else T, Fishbein L, Gill AJ, Tischler AS, Giordano T, Prodanov T, Noble JR, Reddel RR, Trainer AH, Ghayee HK, Bourdeau I, Elston M, Ishak D, Ngeow Yuen Yie J, Hicks RJ, Crona J, ?kerstr?m T, St?lberg P, Dahia P, Grimmond S, Clifton-Bligh R, Pacak K, Tothill RW. Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles. Nat Commun. 2025 Mar 17; 16(1):2632.
-
Panja S, Kapoor E, Siddhanta K, Jogdeo CM, Sil D, Khan RI, Kumari N, Ding L, Gendelman HE, Singh AB, Oupick? D. Bioactive polymers as stimulus-responsive anti-metastatic combination agents to treat pancreatic cancer. Biomaterials. 2025 Sep; 320:123255.
-
Borgers JSW, Lenkala D, Kohler V, Jackson EK, Linssen MD, Hymson S, McCarthy B, O'Reilly Cosgrove E, Balogh KN, Esaulova E, Starr K, Ware Y, Klobuch S, Sciuto T, Chen X, Mahimkar G, Sheen JHF, Ramesh S, Wilgenhof S, van Thienen JV, Scheiner KC, Jedema I, Rooney M, Dong JZ, Srouji JR, Juneja VR, Arieta CM, Nuijen B, Gottstein C, Finney OC, Manson K, Nijenhuis CM, Gaynor RB, DeMario M, Haanen JB, van Buuren MM. Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial. Nat Med. 2025 Mar; 31(3):881-893.
-
Boulton DP, Hughes CJ, Vaira V, Del Gobbo A, Palleschi A, Locatelli M, Danis E, Raza M, Neumann AJ, Purdy SC, Lerma R, Meshki J, Ford HL, Prekeris R, Morrissey C, Caino MC. MIRO2 promotes cancer invasion and metastasis via MYO9B suppression of RhoA activity. Cell Rep. 2025 01 28; 44(1):115120.
-
Patil T, Gao D, Watson A, Sakamoto M, Nie Y, Gibson A, Dean ML, Yoder BA, Miller E, Stalker M, Aisner DL, Bunn PA, Schenk EL, Marmarelis ME, Bennati C, Navani V, Zhang Y, Camidge DR. The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations. Lung Cancer. 2025 Jan; 199:108040.
-
Borazanci EH, Bahary N, Chung V, Huyck TK, Kio EA, Chiorean EG, Skeel RT, Alese OB, Cardin DB, Fountzilas C, Hanna WT, Leal AD, Lee V, Noonan AM, Philip PA, Wainberg ZA, Pashova H, Mann G, Oberstein PE. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. Oncologist. 2024 Nov 04; 29(11):957-965.
-
Abdelazeem KNM, Nguyen D, Corbo S, Darragh LB, Matsumoto MW, Van Court B, Neupert B, Yu J, Olimpo NA, Osborne DG, Gadwa J, Ross RB, Nguyen A, Bhatia S, Kapoor M, Friedman RS, Jacobelli J, Saviola AJ, Knitz MW, Pasquale EB, Karam SD. Manipulating the EphB4-ephrinB2 axis to reduce metastasis in HNSCC. Oncogene. 2025 Feb; 44(3):130-146.
-
Coveler AL, Reilley MJ, Zalupski M, Macarulla T, Fountzilas C, Ponz-Sarvis? M, Nagrial A, Uboha NV, Frentzas S, Overman M, Noonan A, Messersmith WA, Pavlakis N, Mettu NB, Bisha I, Wang Y, Smith P, Murtomaki E, Bielska AA, Bragulat V, Cooper ZA, Kumar R, Spigel DR. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2024 Oct 15; 30(20):4609-4617.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|